17,261 trials
Pancreatic Cancer · Colorectal Cancer · Non-Small Cell Lung Cancer
Primary: Participants With Dose Limiting Toxicities (DLT) — 0; 1; 3; 2 Participants
Influenza
Primary: Number of Participants With Immediate Unsolicited Adverse Events (AEs) After Any Vaccination — 0; 0; 1; 0 Participants
Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS)
Primary: Percent Reduction From Baseline to Week 8 in Frequency of Total Seizures (Normalized to a 4-Week Rate) — 12.6; 0.0 percent reduction of seizures per 4 wks — p=0.5812
Ulcerative Colitis
Primary: Induction Period: Percentage of Participants With Clinical Remission at Week 12 — 4.8; 15.9; 22.6; 11.5 percentage of participants
Completely Resectable Stage IIIB, IIIC, or IVM1a Melanoma
Primary: Recurrence-Free Survival (RFS) — 0.0; 0.0 months — p=0.070
Allergic Rhinitis
Primary: Percent Change From Baseline in Total Nasal Symptom Score (TNSS) Area Under Curve (AUC) (0-1 Hour (hr) Post Peak TNSS) in Response to Post Nasal Allergen Challenge (NAC)…
Respiratory Syncytial Virus
Primary: Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0 — 0; 0; 0 participants
Neurofibromatosis Type 2 · Progressive Vestibular Schwannomas
Primary: Improvement in Hearing — 9 Participants
Chronic Kidney Disease · Type 2 Diabetes Mellitus
Primary: Changes in Urine Albumin to Creatinine Ratio (UACR) — -64.6; 104.8 mg/g — p=0.279
Anal Cancer · Nonneoplastic Condition · Penile Cancer
Primary: Incidence of AIN or Anal/Perianal Condyloma Associated With HPV 6 DNA — 0.0; 11.1 Events per 100 person years — p=0.112
Alopecia Areata
Primary: Change From Baseline in Severity of Alopecia Tool (SALT) Score at Week 24 — 32.54; 50.59; 1.41 units on a scale — p=<.0001
Alcohol Use Disorder
Primary: Time to Relapse — 16; 43 days
MDS (Myelodysplastic Syndrome) · Myeloproliferative Disorder · Lymphoma, Non-Hodgkin
Primary: Overall Survival — 36 Participants
Melanoma
Primary: Percentage of Participants With Relapse Free Survival — 28.6 percentage of participants
Hormone Receptor Positive Breast Cancer · HER-2 Positive Breast Cancer
Primary: Progression Free Survival (PFS) — 8.3; 5.7; 5.7 Months — p=0.0506